Clinical Research Directory

Inclusion Criteria: * Aged 12 to \< 18 years at screening * BMI \>/= 95th percentile based on age and sex at screening * Provide release of information for established primary health provider * Own a device capable of connecting to the virtual platform sessions with video Exclusion Criteria: * Diabetes (type 1 or 2) due to safety concerns about proper surveillance of glycemic control virtually * HbA1c \>/= 6.5% * Current or recent (\< 6 months prior to screening) use of FDA-approved obesity medications * Previous metabolic/bariatric surgery or metabolic/bariatric surgery planned during the study period * Hypertriglyceridemia (TG \>/= 500 mg/dL) * Any past or current diagnosis of an eating disorder (i.e. anorexia nervosa, atypical anorexia nervosa, bulimia nervosa) * Major psychiatric disorder (e.g. schizophrenia, bipolar disorder) * Unstable clinically-diagnosed depression, defined as requiring psychiatric hospitalization in the last six months) * History of suicide attempt * History of suicidal ideation or self-harm within 30 days of screening * Patient Health Questionnaire (PHQ-9) score \>/= 15 at screening * Current pregnancy, breast feeding, or plans to become pregnant * Females refusing to use effective contraception * Diagnosis of monogenic obesity due to mutations in POMC, PCSK1, or LEPR * Diagnosis of syndromic obesity including, but not limited to, Bardet Biedl or Prader-Willi Syndrome * History of cholelithiasis without cholecystectomy * History of pancreatitis * Personal history of first-degree relative history of medullary thyroid carcinoma and/or multiple endocrine neoplasia type 2 * Known hypersensitivity to GLP1 agonists * Other participants from the same household who are participating in this trial * Any disorder, unwillingness, or inability, which in the investigator's opinion might jeopardize the participant's safety or compliance with the protocol